Investigational New Drugs

, Volume 26, Issue 1, pp 81–87 | Cite as

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

  • George R. BlumenscheinJr.
  • Merrill S. Kies
  • Vassiliki A. Papadimitrakopoulou
  • Charles Lu
  • Ashok J. Kumar
  • Justin L. Ricker
  • Judy H. Chiao
  • Cong Chen
  • Stanley R. Frankel
PHASE II STUDIES

Summary

This phase II trial was initiated to assess the efficacy and safety of oral vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Eligible patients must have recurrent and/or metastatic head and neck cancer unresponsive to or intolerant of conventional chemotherapy. Patients must have measurable disease, adequate hematologic, hepatic, and renal function, and be able to swallow capsules. Four or more weeks must have elapsed since prior chemotherapy, radiation therapy, major surgery or investigational anticancer therapy, and patients must have recovered from prior toxicities. Study endpoints included response rate, duration of stable disease and progression-free survival. Thirteen patients were enrolled (9 males); 1 withdrew consent prior to starting therapy. Twelve patients received oral vorinostat 400 mg once daily and were evaluable for response. The median age was 54 years (range 40–82). All patients had received prior chemotherapy (including 10 with platinum- or taxane-based combination therapy), and 9 had prior radiation therapy. No confirmed partial or complete responses were observed. One unconfirmed partial response was seen. Three patients had stable disease ranging from 9 to 26 weeks. Nine patients discontinued due to progressive disease, two withdrew consent, and one discontinued therapy for grade 3 anorexia. Grades 3–4 drug-related toxicities included thrombocytopenia (n = 3), anorexia (n = 2), and dehydration (n = 2). Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients.

Keywords

HDAC Head and neck cancer Histone deacetylase inhibitor Metastatic Phase II Recurrent SAHA SCCHN Suberoylanilide hydroxamic acid Vorinostat 

References

  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 97:1407–1427PubMedCrossRefGoogle Scholar
  3. 3.
    Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ (2006) Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 24:190–205PubMedCrossRefGoogle Scholar
  4. 4.
    Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654PubMedCrossRefGoogle Scholar
  5. 5.
    Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA (2004) Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262–268PubMedCrossRefGoogle Scholar
  6. 6.
    Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202PubMedCrossRefGoogle Scholar
  7. 7.
    Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971–3993PubMedCrossRefGoogle Scholar
  8. 8.
    Weidle UH, Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20:1471–1485PubMedGoogle Scholar
  9. 9.
    Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293–304PubMedCrossRefGoogle Scholar
  10. 10.
    Takumi S, Katsuhiro U, Takeshi O, Masashi S, Hidetaka Y, Takahiko S, Hideki T (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29:117–124Google Scholar
  11. 11.
    Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003–3007PubMedCrossRefGoogle Scholar
  12. 12.
    Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236–3239PubMedCrossRefGoogle Scholar
  13. 13.
    Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33:53–61PubMedCrossRefGoogle Scholar
  14. 14.
    Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB (2006) suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-{kappa}B activation. J Biol Chem 281:5612–5622PubMedCrossRefGoogle Scholar
  15. 15.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11:6382–6389PubMedCrossRefGoogle Scholar
  16. 16.
    Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP (2003) Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 9:5749–5755PubMedGoogle Scholar
  17. 17.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165–5170PubMedGoogle Scholar
  18. 18.
    Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM (2002) Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22:1497–1504PubMedGoogle Scholar
  19. 19.
    Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931PubMedCrossRefGoogle Scholar
  20. 20.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  21. 21.
    Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85PubMedCrossRefGoogle Scholar
  22. 22.
    Vermorken J, Bourhis J, Trigo J, Kies M, Leon X, Mueser M, Amellal N, Scheler A, Baselga J (2005) Cetuximab (Erbitux®) in recurrent/metstatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J Clin Oncol 23:501s (Abstract)Google Scholar
  23. 23.
    Amer MH, Al Sarraf M, Vaitkevicius VK (1979) Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43:2202–2206PubMedCrossRefGoogle Scholar
  24. 24.
    Colevas AD (2006) Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24:2644–2652PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE (2005) Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418–8424PubMedCrossRefGoogle Scholar
  26. 26.
    Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM (2005) A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 41:523–530PubMedCrossRefGoogle Scholar
  27. 27.
    Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, Forastiere AA (2004) Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Investig 22:823–831CrossRefGoogle Scholar
  28. 28.
    Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, Rolland F, Dittrich C, Baron B, Lacombe D, Fumoleau P (2004) Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer 40:2748–2752PubMedGoogle Scholar
  29. 29.
    Pfister DG, McCaffrey J, Zahalsky AJ, Schwartz GK, Lis E, Gerald W, Huvos A, Shah J, Kraus D, Shaha A, Singh B, Wolden S, Zelefsky M, Palgi I (2002) A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest New Drugs 20:123–127PubMedCrossRefGoogle Scholar
  30. 30.
    Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562–3567PubMedCrossRefGoogle Scholar
  31. 31.
    Schena M, Barone C, Birocco N, Dongiovanni D, Numico G, Colantonio I, Bertetto O (2005) Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. Cancer Chemother Pharmacol 55:271–276PubMedCrossRefGoogle Scholar
  32. 32.
    Caponigro F, Rosati G, De Rosa P, Avallone A, De Rosa V, De Lucia L, Comella P, Comella G (2002) Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. Oncology 63:232–238PubMedCrossRefGoogle Scholar
  33. 33.
    Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, Oliveira J, Lewensohn R, Schuller J, Riviere A, Arvay C, Langecker P, Jacob H, Cvitkovic E, Vokes E (1998) Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16:1054–1059PubMedGoogle Scholar
  34. 34.
    Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291–7300PubMedGoogle Scholar
  35. 35.
    Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C (2005) The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131:385–394PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang Y, Jung M, Dritschilo A, Jung M (2004) Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161:667–674PubMedCrossRefGoogle Scholar
  37. 37.
    Sgouros G, Yang WH, Richon VM, Kelly WK, Rifkind RA, Marks PA (2002) Synergistic interaction of suberoylanilide hydroxamic acid (SAHA) and radiation in human prostate cancer spheroids. Proc Am Soc Clin Oncol #105 (Abstract)Google Scholar
  38. 38.
    Biade S, Stobbe CC, Boyd JT, Chapman JD (2001) Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 77:1033–1042PubMedCrossRefGoogle Scholar
  39. 39.
    Ferrandina G, Filippini P, Ferlini C, Maggiano N, Stoler AB, Fruscella E, Mozzetti S, Mancuso S, Freedman RS, Scambia G, Ranelletti FO (2000) Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol Res 12:429–440PubMedGoogle Scholar
  40. 40.
    Miller AC, Whittaker T, Thibault A, Samid D (1997) Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int J Radiat Biol 72:211–218PubMedCrossRefGoogle Scholar
  41. 41.
    Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005) Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther 4:1231–1238PubMedCrossRefGoogle Scholar
  42. 42.
    Jung M, Velena A, Chen B, Petukhov PA, Kozikowski AP, Dritschilo A (2005) Novel HDAC inhibitors with radiosensitizing properties. Radiat Res 163:488–493PubMedCrossRefGoogle Scholar
  43. 43.
    Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912–4922PubMedCrossRefGoogle Scholar
  44. 44.
    Chung YL, Wang AJ, Yao LF (2004) Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 3:317–325PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • George R. BlumenscheinJr.
    • 1
  • Merrill S. Kies
    • 1
  • Vassiliki A. Papadimitrakopoulou
    • 1
  • Charles Lu
    • 1
  • Ashok J. Kumar
    • 1
  • Justin L. Ricker
    • 2
  • Judy H. Chiao
    • 2
  • Cong Chen
    • 2
  • Stanley R. Frankel
    • 2
  1. 1.Department of Thoracic and Head and Neck Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Merck Research LaboratoriesUpper GwyneddUSA

Personalised recommendations